Format

Send to

Choose Destination
World J Hepatol. 2015 Dec 18;7(29):2859-70. doi: 10.4254/wjh.v7.i29.2859.

Wilson's disease: A review of what we have learned.

Author information

1
Kryssia Isabel Rodriguez-Castro, Gastroenterology and Endoscopy, Policlinico Abano Terme, 35031 Abano Terme, Padua, Italy.

Abstract

Wilson's disease (WD), which results from the defective ATP7B protein product, is characterized by impaired copper metabolism and its clinical consequences vary from an asymptomatic state to fulminant hepatic failure, chronic liver disease with or without cirrhosis, neurological, and psychiatric manifestations. A high grade of suspicion is warranted to not miss cases of WD, especially less florid cases with only mild elevation of transaminases, or isolated neuropsychiatric involvement. Screening in first and second relatives of index cases is mandatory, and treatment must commence upon establishment of diagnosis. Treatment strategies include chelators such as D-penicillamine and trientine, while zinc salts act as inductors of methallothioneins, which favor a negative copper balance and a reduction of free plasmatic copper. As an orphan disease, research is lacking in this field, especially regarding therapeutic strategies which are associated with better patient compliance and which could eventually also reverse established injury.

KEYWORDS:

Chelating agents; Copper; Liver transplantation; Orphan disease; Penicillamine; Wilson disease; Wilson’s disease; Zinc

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center